| 000 | 02886 a2200721 4500 | ||
|---|---|---|---|
| 005 | 20250513223649.0 | ||
| 264 | 0 | _c20010308 | |
| 008 | 200103s 0 0 eng d | ||
| 022 | _a1083-8791 | ||
| 024 | 7 |
_a10.1016/s1083-8791(00)70065-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohnston, L J | |
| 245 | 0 | 0 |
_aToxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma. _h[electronic resource] |
| 260 |
_bBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation _c2000 |
||
| 300 |
_a555-62 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAcute Kidney Injury _xchemically induced |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Marrow Diseases _xchemically induced |
| 650 | 0 | 4 | _aBone Marrow Purging |
| 650 | 0 | 4 |
_aCardiomyopathies _xchemically induced |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _xetiology |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aCystitis _xchemically induced |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Mobilization _xadverse effects |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xadverse effects |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfections |
| 650 | 0 | 4 |
_aLeucovorin _xadministration & dosage |
| 650 | 0 | 4 | _aLife Tables |
| 650 | 0 | 4 |
_aLymphoma, Non-Hodgkin _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xadministration & dosage |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitoxantrone _xadministration & dosage |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xadverse effects |
| 650 | 0 | 4 | _aTransplantation, Autologous |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVincristine _xadministration & dosage |
| 700 | 1 | _aStockerl-Goldstein, K E | |
| 700 | 1 | _aHu, W W | |
| 700 | 1 | _aNegrin, R S | |
| 700 | 1 | _aHoppe, R T | |
| 700 | 1 | _aBlume, K G | |
| 700 | 1 | _aHorning, S J | |
| 773 | 0 |
_tBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation _gvol. 6 _gno. 5A _gp. 555-62 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1083-8791(00)70065-6 _zAvailable from publisher's website |
| 999 |
_c11013086 _d11013086 |
||